MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
-0.020
-1.79%
Opening 11:07 06/24 EDT
OPEN
1.110
PREV CLOSE
1.120
HIGH
1.130
LOW
1.080
VOLUME
384.07K
TURNOVER
--
52 WEEK HIGH
3.500
52 WEEK LOW
0.6320
MARKET CAP
49.25M
P/E (TTM)
-2.6005
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 6d ago
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, In...
GlobeNewswire · 06/17 12:03
Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat
Benzinga · 06/15 15:45
Salarius Pharmaceuticals Announces New Clinical Trial To Study Seclidemstat In Hematologic Cancers
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the
Benzinga · 06/15 11:30
Salarius Pharmaceuticals Conducts Clinical Study of Seclidemstat in Blood Cancers
MT Newswires · 06/15 08:09
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc...
GlobeNewswire · 06/10 17:30
Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients
Benzinga · 06/07 14:19
Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Salarius Pharmaceuticals (SLRX) presents key findings from clinical research involving seclidemstat at the 2021 ASCO Annual Meeting, held June 4-8.The results included data on seclidemstat’s safety, dosing and early efficacy
Seekingalpha · 06/07 12:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLRX. Analyze the recent business situations of Salarius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLRX stock price target is 4.100 with a high estimate of 5.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 15.53M
% Owned: 34.69%
Shares Outstanding: 44.77M
TypeInstitutionsShares
Increased
13
3.89M
New
15
7.54M
Decreased
1
3.03K
Sold Out
5
164.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.76%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
William McVicar
President/Chief Executive Officer/Director
David Arthur
Chief Financial Officer/Executive Vice President - Finance
Mark Rosenblum
Chief Operating Officer
Kathie Lindemann
Senior Vice President
Nadeem Mirza
Chief Scientific Officer/Director
Bruce McCreedy
Chief Scientific Officer/Director
Bruce Mccreedy
Lead Director/Independent Director
Paul Lammers
Independent Director
Tess Burleson
Independent Director
Arnold Hanish
Independent Director
Jonathan Lieber
No Data
  • All
  • Financials
  • Insiders
More
About SLRX
Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.